Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Double-blind Parallel Group Trial to Study the Effects of an Infant Formula Containing Partially Hydrolysed Proteins on Growth and Tolerance in Healthy Term Infants

NCT05757323 is registered in ClinicalTrials.gov with FrieslandCampina as lead sponsor.

NCT NCT05757323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05757323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Double-blind Parallel Group Trial to Study the Effects of an Infant Formula Containing Partially Hydrolysed Proteins on Growth and Tolerance in Healthy Term Infants
Lead sponsor
FrieslandCampina
Phase
Not applicable
Overall status
Completed
Start date
August 6, 2021
Completion date
October 24, 2022
Enrollment
345 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

growth